Literature DB >> 32502289

Reply to: SARS-CoV-2 as a Potential Trigger of Neurodegenerative Diseases.

Tiago F Outeiro1,2,3, Anita Krisko1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32502289      PMCID: PMC7300978          DOI: 10.1002/mds.28178

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   9.698


× No keyword cloud information.
We are excited that our article has attracted the attention of other colleagues, as we believe that given the current coronavirus diesease 2019 (COVID‐19) pandemic it is essential to consider the potential long‐term implications of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infections. In particular, as Gomez‐Pinedo and colleagues point out, it is known that coronaviruses can be found in the central nervous system of elderly people and of patients with Alzheimer's disease, Parkinson's disease, or multiple sclerosis. In the few months that SARS‐CoV‐2 has been storming the planet, our perception of the virus has evolved from a virus that causes a severe respiratory disease to a virus that can also severely impact the central nervous system and that may likely trigger long‐term consequences we cannot fully anticipate. Part of the deadly capability of SARS‐CoV‐2 is its tight binding to the human angiotensin converting enzyme 2 receptor, with more than 20‐fold higher affinity (~15 nM) compared with its predecessor SARS‐CoV. , Interestingly, efforts to describe the mechanism of virus neutralization by antibodies have so far revealed that the antibodies bind the spike protein core, rather than the receptor binding domain. , These observations may open new avenues in treatment and vaccine development. As we wrote in Lippi and colleagues, aging and several preexisting health conditions remain as the main risk factors for the severity of COVID‐19. The common denominator to all these risk factors is the decreased performance of the immune system. Senescence of the immune system may shed light into the differences in COVID‐19 adversity between young and old individuals as well as between men and women. For example, B lymphocyte depletion is characteristic of old age, affecting predominantly men. , Such changes in the immune system lead to “inflammaging,” a term describing the presence of low‐grade inflammation at an advanced age, also consistent with the gender bias of SARS‐CoV‐2. The stronger age‐dependent activation of the innate proinflammatory pathways in COVID‐19 is observed in men, which is consistent with a higher rate of inflammaging also among men. Inflammaging may trigger the onset and contribute to the progression of age‐related diseases, including those involving the central nervous system (eg, Alzheimer's disease). Strikingly, in a very recent case report, the neuropathological analysis of the brain of a COVID‐19 patient revealed a range of neuropathological lesions with features indicative of vascular and demyelinating alterations, consistent with parainfections processes affecting COVID‐19 patients. Therefore, we believe it will be critical to implement programs to follow individuals who survived SARS‐CoV‐2 infections over time, and those countries who are capable of implementing such programs will be better equipped to provide the best care for their populations.

Author Roles

(1) Manuscript: A. Writing of the first draft. T.F.O.: 1A A.K.: 1A

Financial Disclosures of all authors (for the preceding 12 months)

A.K. and T.F.O. have received funding from Deutsche Forschungsgemeinshaft in Germany.
  14 in total

1.  A human monoclonal antibody blocking SARS-CoV-2 infection.

Authors:  Chunyan Wang; Wentao Li; Dubravka Drabek; Nisreen M A Okba; Rien van Haperen; Albert D M E Osterhaus; Frank J M van Kuppeveld; Bart L Haagmans; Frank Grosveld; Berend-Jan Bosch
Journal:  Nat Commun       Date:  2020-05-04       Impact factor: 14.919

Review 2.  Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases.

Authors:  Claudio Franceschi; Judith Campisi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-06       Impact factor: 6.053

3.  Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology.

Authors:  R Ross Reichard; Kianoush B Kashani; Nicholas A Boire; Eleni Constantopoulos; Yong Guo; Claudia F Lucchinetti
Journal:  Acta Neuropathol       Date:  2020-05-24       Impact factor: 17.088

4.  Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes.

Authors:  Massimiliano Bonafè; Francesco Prattichizzo; Angelica Giuliani; Gianluca Storci; Jacopo Sabbatinelli; Fabiola Olivieri
Journal:  Cytokine Growth Factor Rev       Date:  2020-05-03       Impact factor: 7.638

5.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

Authors:  Yuanyuan Zhang; Yaning Li; Renhong Yan; Lu Xia; Yingying Guo; Qiang Zhou
Journal:  Science       Date:  2020-03-04       Impact factor: 47.728

Review 6.  SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes.

Authors:  Janko Nikolich-Zugich; Kenneth S Knox; Carlos Tafich Rios; Bhupinder Natt; Deepta Bhattacharya; Mindy J Fain
Journal:  Geroscience       Date:  2020-04-10       Impact factor: 7.713

Review 7.  Inflammaging as a prodrome to Alzheimer's disease.

Authors:  Brian Giunta; Francisco Fernandez; William V Nikolic; Demian Obregon; Elona Rrapo; Terrence Town; Jun Tan
Journal:  J Neuroinflammation       Date:  2008-11-11       Impact factor: 8.322

8.  SARS-CoV-2 as a Potential Trigger of Neurodegenerative Diseases.

Authors:  Ulises Gomez-Pinedo; Jorge Matias-Guiu; Inmaculada Sanclemente-Alaman; Lidia Moreno-Jimenez; Paloma Montero-Escribano; Jordi A Matias-Guiu
Journal:  Mov Disord       Date:  2020-07       Impact factor: 9.698

9.  Is the brain a reservoir organ for SARS-CoV2?

Authors:  Ulises Gomez-Pinedo; Jorge Matias-Guiu; Inmaculada Sanclemente-Alaman; Lidia Moreno-Jimenez; Paloma Montero-Escribano; Jordi A Matias-Guiu
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 20.693

10.  SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration.

Authors:  Alice Lippi; Renato Domingues; Cristian Setz; Tiago F Outeiro; Anita Krisko
Journal:  Mov Disord       Date:  2020-04-24       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.